The neurology clinical trials market is expected to register a CAGR of 4.35% during the forecast period (2022-2027).
Covid-19 was an unprecedented event that has impacted nearly every aspect of businesses around the world. The ongoing clinical trials were delayed with disruptions to trial enrolment, data collection, and data analysis. A study titled "Impact of Covid-19 pandemic on clinical trials evaluating various neurology indications" published in April 2020 mentioned that a total of 81 trials with a definite neurology indication were identified as of April 2020. Indications related to pain and mental health are the most dominant, with 21% and 19% of the total indications. Also, the source mentioned that 11% of the trials evaluating various forms of addiction were impacted by the crisis.
However, the Covid-19 disease affects older people as well as people with underlying comorbidities. Neurological diseases are a common cause of mortality rate in an older population. People with dementia, for instance, majorly live with one or more chronic health conditions. As per Alzheimer's Disease International, more than 55 million people were living with dementia worldwide in 2020. And the risk of getting infected with Covid-19 was high for this target population. The memory impairment linked to dementia might interfere with the patient's ability to cooperate with preventive measures for COVID-19 like social distancing, mask-wearing, frequent hand sanitizing, and others. This led to much research and development. Hence, it is expected to have a positive impact on neurology clinical trials.
An increasing number of companies conducting clinical trials in neurology, the rising prevalence of various neurological diseases, and increasing research and development (R&D) investments and government funding towards neurological research are anticipated to drive the studied market growth.
According to Pan American Health Organization (PAHO), in 2019, regionwide neurological conditions accounted for 533,172 total deaths, among which 213,129 (40%) in men and 320,043 (60%) in women in North America.
In addition, a study entitled "Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: A systematic review and meta-analysis" published in December 2020 showed when a total of 56,577 patients were taken for the study, the prevalence of dementia in this pooled analysis was 10%. Both adjusted and unadjusted effects for dementia associated with increased mortality were 72.9% and 93.7%, respectively. This burden of neurological diseases is expected to increase in the coming years, driving the demand for advanced therapies and treatments for neurological diseases. This is poised to drive the growth of the studied market.
However, stringent regulatory demand related to clinical trials and high failure rates, and increasing cost of clinical trials is anticipated to hinder the market growth over the forecast period.
Alzheimer's Disease or AD is expected to boost the demand for neurology clinical trials and will grow at a stable growth rate in the forecast period.
Alzheimer's disease is one of the major problems in neuroscience, and it is majorly thought to be caused by an abnormal build-up of proteins inside and around brain cells. But it is still unknown what triggers Alzheimer's Disease (AD). The primary symptoms are problems with vision or language, while with the disease, different areas of the brain are affected, primarily those associated with memory.
According to National Health Service (NHS), although the factors causing this disease are unknown, there are several factors that are known that increase the risk of getting this disease. Such as age, family history, people living with Down's syndrome, Head injuries, and cardiovascular diseases are more prone to be affected by this disease.
The Alzheimer's Association 2021 report shows that the United States Food and Drug Administration (US FDA) has approved five drugs for the treatment of Alzheimer's, namely rivastigmine, galantamine, donepezil, memantine, and memantine combined with donepezil.
Additionally, in the article published by Alzheimer's Association titled "Alzheimer's disease drug development pipeline: 2021", there were 121 agents in clinical trials for the treatment of Alzheimer's disease. Twenty‐nine agents are in 36 Phase 3 trials, 65 agents are in 73 Phase 2 trials, and 27 agents are in 27 Phase 1 trials. Twelve agents in trials target cognitive enhancement, and 12 are intended to treat neuropsychiatric and behavioral symptoms. There were 97 agents in disease modification trials as of February 2020.
Owing to the increasing number of clinical trials and drug approvals, the Alzheimer's Disease segment by indication is expected to grow over the forecast period. Hence, driving the growth of the studied market.
Factors such as high treatment awareness among the target population across the country, healthcare infrastructure, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations are driving the growth of the United States neurology clinical trials market.
North America currently dominates the market for clinical trials for diagnostics and therapeutics, and it is expected to continue its stronghold for a few more years. The United States is anticipated to hold the largest share of the market.
According to a report published in March 2021, Alzheimer's Disease Facts and Figures, by 2050, this number is projected to rise to nearly 13 million. Additionally, the Centre for Disease Control and Prevention (CDC) data updated in April 2022 that every 40 seconds, someone in the United States has a stroke, and every 3.5 minutes, someone dies of a stroke. This burden of neurological disorders such as Alzheimer's Disease, stroke, and others is expected to drive the demand for new therapeutics in the market. Hence it is poised to drive the growth of the studied market.
In addition, as per CDC, stroke is a leading cause of serious long-term disability and reduces mobility in more than half of stroke survivors of age 65 and older in the United States. The geriatric population is one of the key factors responsible for the market growth in this country, as the older population is at a higher risk of acquiring this disease. The United States Census Bureau data, in 2019, about 54 million Americans were aged 65 years and above.
Therefore, owing to the aforementioned factors, the North American region is expected to witness strong growth over the forecast period driving the growth of the neurology clinical trials market.
In the current scenario, the number of product launches, collaborations, and other strategies by the market players is increasing, and it's fueling the global neurology clinical trial market. The market is competitive in nature globally and fragmented due to the presence of several major players in the market. Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals), AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd., Eli Lilly and Company, Aurora Health Care, AbbVie Inc., Zydus Group, Athira Pharma, Inc., Annovis Bio, Biogen, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Sanofi are some of the major players among others.
This product will be delivered within 2 business days.
Covid-19 was an unprecedented event that has impacted nearly every aspect of businesses around the world. The ongoing clinical trials were delayed with disruptions to trial enrolment, data collection, and data analysis. A study titled "Impact of Covid-19 pandemic on clinical trials evaluating various neurology indications" published in April 2020 mentioned that a total of 81 trials with a definite neurology indication were identified as of April 2020. Indications related to pain and mental health are the most dominant, with 21% and 19% of the total indications. Also, the source mentioned that 11% of the trials evaluating various forms of addiction were impacted by the crisis.
However, the Covid-19 disease affects older people as well as people with underlying comorbidities. Neurological diseases are a common cause of mortality rate in an older population. People with dementia, for instance, majorly live with one or more chronic health conditions. As per Alzheimer's Disease International, more than 55 million people were living with dementia worldwide in 2020. And the risk of getting infected with Covid-19 was high for this target population. The memory impairment linked to dementia might interfere with the patient's ability to cooperate with preventive measures for COVID-19 like social distancing, mask-wearing, frequent hand sanitizing, and others. This led to much research and development. Hence, it is expected to have a positive impact on neurology clinical trials.
An increasing number of companies conducting clinical trials in neurology, the rising prevalence of various neurological diseases, and increasing research and development (R&D) investments and government funding towards neurological research are anticipated to drive the studied market growth.
According to Pan American Health Organization (PAHO), in 2019, regionwide neurological conditions accounted for 533,172 total deaths, among which 213,129 (40%) in men and 320,043 (60%) in women in North America.
In addition, a study entitled "Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: A systematic review and meta-analysis" published in December 2020 showed when a total of 56,577 patients were taken for the study, the prevalence of dementia in this pooled analysis was 10%. Both adjusted and unadjusted effects for dementia associated with increased mortality were 72.9% and 93.7%, respectively. This burden of neurological diseases is expected to increase in the coming years, driving the demand for advanced therapies and treatments for neurological diseases. This is poised to drive the growth of the studied market.
However, stringent regulatory demand related to clinical trials and high failure rates, and increasing cost of clinical trials is anticipated to hinder the market growth over the forecast period.
Key Market Trends
Alzheimer’s Disease by Indication is Expected to Grow Over the Forecast Period
Alzheimer's Disease or AD is expected to boost the demand for neurology clinical trials and will grow at a stable growth rate in the forecast period.
Alzheimer's disease is one of the major problems in neuroscience, and it is majorly thought to be caused by an abnormal build-up of proteins inside and around brain cells. But it is still unknown what triggers Alzheimer's Disease (AD). The primary symptoms are problems with vision or language, while with the disease, different areas of the brain are affected, primarily those associated with memory.
According to National Health Service (NHS), although the factors causing this disease are unknown, there are several factors that are known that increase the risk of getting this disease. Such as age, family history, people living with Down's syndrome, Head injuries, and cardiovascular diseases are more prone to be affected by this disease.
The Alzheimer's Association 2021 report shows that the United States Food and Drug Administration (US FDA) has approved five drugs for the treatment of Alzheimer's, namely rivastigmine, galantamine, donepezil, memantine, and memantine combined with donepezil.
Additionally, in the article published by Alzheimer's Association titled "Alzheimer's disease drug development pipeline: 2021", there were 121 agents in clinical trials for the treatment of Alzheimer's disease. Twenty‐nine agents are in 36 Phase 3 trials, 65 agents are in 73 Phase 2 trials, and 27 agents are in 27 Phase 1 trials. Twelve agents in trials target cognitive enhancement, and 12 are intended to treat neuropsychiatric and behavioral symptoms. There were 97 agents in disease modification trials as of February 2020.
Owing to the increasing number of clinical trials and drug approvals, the Alzheimer's Disease segment by indication is expected to grow over the forecast period. Hence, driving the growth of the studied market.
North America is Expected to Dominate the Market in the Forecast Period
Factors such as high treatment awareness among the target population across the country, healthcare infrastructure, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations are driving the growth of the United States neurology clinical trials market.
North America currently dominates the market for clinical trials for diagnostics and therapeutics, and it is expected to continue its stronghold for a few more years. The United States is anticipated to hold the largest share of the market.
According to a report published in March 2021, Alzheimer's Disease Facts and Figures, by 2050, this number is projected to rise to nearly 13 million. Additionally, the Centre for Disease Control and Prevention (CDC) data updated in April 2022 that every 40 seconds, someone in the United States has a stroke, and every 3.5 minutes, someone dies of a stroke. This burden of neurological disorders such as Alzheimer's Disease, stroke, and others is expected to drive the demand for new therapeutics in the market. Hence it is poised to drive the growth of the studied market.
In addition, as per CDC, stroke is a leading cause of serious long-term disability and reduces mobility in more than half of stroke survivors of age 65 and older in the United States. The geriatric population is one of the key factors responsible for the market growth in this country, as the older population is at a higher risk of acquiring this disease. The United States Census Bureau data, in 2019, about 54 million Americans were aged 65 years and above.
Therefore, owing to the aforementioned factors, the North American region is expected to witness strong growth over the forecast period driving the growth of the neurology clinical trials market.
Competitive Landscape
In the current scenario, the number of product launches, collaborations, and other strategies by the market players is increasing, and it's fueling the global neurology clinical trial market. The market is competitive in nature globally and fragmented due to the presence of several major players in the market. Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals), AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd., Eli Lilly and Company, Aurora Health Care, AbbVie Inc., Zydus Group, Athira Pharma, Inc., Annovis Bio, Biogen, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Sanofi are some of the major players among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals)
- AstraZeneca
- Novartis AG
- Eisai Co., Ltd.
- Eli Lilly and Company
- Aurora Health Care
- AbbVie Inc.
- Zydus Group
- Athira Pharma, Inc.
- Annovis Bio
- Biogen
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
Methodology
LOADING...
